PRPS1/PRPS2/PRPS1L1 Antibody



PACO18615

Product Information

Size:

50ul

Reactivity:

Human, Mouse

Source:

Rabbit

Isotype:

lgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

Protein Background:

Serine/threonine-protein kinase involved in cell polarity and microtubule dynamics regulation. Phosphorylates CRTC2/TORC2, DCX, HDAC7, KIF13B, MAP2, MAP4, MAPT/TAU, and RAB11FIP2. Plays a key role in cell polarity by phosphorylating the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS motifs, causing detachment from microtubules, and their disassembly. Regulates epithelial cell polarity by phosphorylating RAB11FIP2. Involved in the regulation of neuronal migration through its dual activities in regulating cellular polarity and microtubule dynamics, possibly by phosphorylating and regulating DCX. Regulates axogenesis by phosphorylating KIF13B, promoting interaction between KIF13B and 14-3-3 and inhibiting microtubule-dependent accumulation of KIF13B. Also required for neurite outgrowth and establishment of neuronal polarity. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus.

Gene ID:

PRPS1/PRPS2/PRPS1L1

Uniprot

P60891/P11908/P21108

Synonyms:

phosphoribosyl pyrophosphate synthetase 1/2/1-like 1


Immunogen:

Synthetic peptide of human PRPS1/2/1L1.


Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Product Images



Gel: 8%SDS-PAGE, Lysate: 40 μ g, Lane: 293T cells, Primary antibody: PACO18615(PRPS1/2/1L1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO18615(PRPS1/2/1L1 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).